By Adriano Marchese
Canopy Growth's loss narrowed in its fiscal second quarter thanks to strong performance in both medical- and recreational-cannabis sales in Canada.
For the three months ended Sept. 30, the Smiths Falls, Ontario, cannabis company on Friday posted a significantly narrowed net loss of 1.64 million Canadian dollars ($1.12 million), or C$0.01 a share, compared with a loss of C$128.3 million, or C$1.48 a share, in the comparable quarter a year earlier.
According to FactSet, analysts were expecting a loss of C$0.16 a share.
Consolidated net revenue rose 6% to C$66.7 million, but fell short of analyst expectations for a greater rise to C$71.2 million.
Canopy said it saw a 30% rise in Canadian adult-use cannabis revenue, to C$24 million, thanks largely to growth in infused preroll joints and new all-in-one vapes. Canadian medical cannabis also got a boost, with revenue rising 17% to C$22 million as it benefited mainly from more insured patients and larger order sizes.
On the international front, Canopy faced supply-chain issues in Europe that dragged revenue down 39% to C$5 million.
Meanwhile, vaporizer brand Storz & Bickel's net revenue fell 10% in the quarter. The brand was up against strong year-earlier figures, as well as continued economic uncertainty in its key markets.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 07, 2025 07:56 ET (12:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Comments